Results 71 to 80 of about 22,047 (159)

Apixaban and clopidogrel in a fixed-dose combination: Formulation and in vitro evaluation

Saudi Pharmaceutical Journal
Fixed-dose combination (FDC) products represent a novel, safe, and cost-effective formulation. Combined use of anticoagulant and antiplatelet medications is common among comorbid cardiovascular patients.
Ni'meh Al-Shami, Hani Naseef, Feras Kanaze   +2 more
doaj   +1 more source

Cardiorenal Outcomes of Dapagliflozin vs. Empagliflozin in Advanced Chronic Kidney Disease and Diabetes

Clinical Pharmacology &Therapeutics, Volume 120, Issue 1, Page 168-177, July 2026.
Target trial emulation of a multi‐institutional electronic health record network showed comparable cardiorenal effectiveness and safety of dapagliflozin versus empagliflozin in adults with type 2 diabetes and advanced‐stage chronic kidney disease.
Shih‐Hsuan Lin, Jia‐Jin Chen, Ching‐Chung Hsiao, Yu‐Wei Fang, Meng‐Ting Chen, Ming‐Hsien Tsai, Huang‐Yu Yang   +6 more
wiley   +1 more source

The effect of apixaban on the pharmacokinetics of digoxin and atenolol in healthy subjects

Clinical Pharmacology: Advances and Applications, 2017
Charles Frost,1 Yan Song,1 Zhigang Yu,2 Jessie Wang,3 Lois S Lee,4 Alan Schuster,5 Allyson Pollack,1 Frank LaCreta1 1Exploratory Clinical and Translational Research, Bristol-Myers Squibb, Princeton, NJ, USA; 2Medical Sciences, Amgen Asia R&D Center ...
Frost C, Song Y, Yu Z, Wang J, Lee LS, Schuster A, Pollack A, LaCreta F   +7 more
doaj  

Chronic Expanding Hematoma Complicated by Life Threatening Hemoptysis and Respiratory Arrest—A Case Report

Respirology Case Reports, Volume 14, Issue 7, July 2026.
In this report, we describe a patient with the rare diagnosis of chronic expanding hematoma, leading to life‐threatening hemoptysis and ultimately type 2 respiratory failure. This case highlights the importance of proactive management for CEH due to its potentially fatal complications.
Anthony Shing‐yiu Yu, Chung Yin Cheung, Chor Ting Ng, Chi Ching Chan, Ying Fung Lo, Judianna Suet Ying Yu, Wallace Hon Cheung Fan, Alwin Wai Tak Yeung   +7 more
wiley   +1 more source

Diagnostic Impact of Liver Biopsy Among Antinuclear Antibody Positive Individuals With Mild Liver Enzyme Elevation

Alimentary Pharmacology &Therapeutics, Volume 64, Issue 1, Page 103-111, July 2026.
In ANA‐positive patients with suspected autoimmune hepatitis (AIH), liver biopsy rarely altered therapeutic management when alanine aminotransferase (ALT) was below 101 U/L and cirrhosis was absent. These findings suggest that biopsy may be safely deferred in this low‐risk group.
David Mehdi Asgher Niazi, Alphonse Charbel, Jan Pfeiffenberger, Uta Merle, Jessica Seessle, Theresa Wenz, Christa Flechtenmacher, Patrick Michl, Conrad Rauber   +8 more
wiley   +1 more source

Association of SGLT2 Inhibitor With Stroke in Type 2 Diabetes With Diabetic Retinopathy: A Multicenter Electronic Health Record Data Study

Diabetes, Obesity and Metabolism, Volume 28, Issue 7, Page 5614-5626, July 2026.
ABSTRACT Aims Diabetic retinopathy (DR) is linked to elevated risks of cerebrovascular diseases. Whether sodium‐glucose cotransporter‐2 inhibitors (SGLT2i) reduce stroke risk in patients with type 2 diabetes (T2D) and DR remains uncertain. Materials and Methods We conducted a retrospective cohort study using the TriNetX Research Network.
Kuo‐En Chen, Po‐Chun Wang, Hui‐An Lin, Sheng‐Feng Lin   +3 more
wiley   +1 more source

Apixaban Concentrations and Effects on Coagulation in Patients With Nephrotic Syndrome

Kidney Medicine
Rationale & Objective: Venous thromboembolism is a serious complication of nephrotic syndrome (NS). Guidelines recommend prophylactic anticoagulation with warfarin or low molecular weight heparin.
Sarah Kelddal, Erik L. Grove, Camilla L. Duus, Louis B. Nygaard, Tilde Kristensen, Frank H. Mose, Jon W. Gregersen, Anne-Mette Hvas, Henrik Birn   +8 more
doaj   +1 more source

Apixaban Reduces Hospitalizations in Patients With Venous Thromboembolism: An Analysis of the Apixaban for the Initial Management of Pulmonary Embolism and Deep‐Vein Thrombosis as First‐Line Therapy (AMPLIFY) Trial

Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease, 2015
Background In the Apixaban for the Initial Management of Pulmonary Embolism and Deep‐Vein Thrombosis as First‐Line Therapy (AMPLIFY) trial, apixaban was noninferior to enoxaparin/warfarin in preventing recurrent symptomatic venous thromboembolism (VTE ...
Xianchen Liu, Margot Johnson, Jack Mardekian, Hemant Phatak, John Thompson, Alexander T. Cohen   +5 more
doaj   +1 more source

Clinical characteristics of apixaban prescription in AF patients with single dose-reduction criterion: the ASPIRE (efficAcy and safety of aPixaban in rEal-world practice in Korean frail patients with atrial fibrillation) study

Frontiers in Cardiovascular Medicine
BackgroundData on off-label reduced dose risk among patients with atrial fibrillation (AF) who qualify for a single-dose reduction of apixaban is scarce.ObjectivesWe prospectively assessed apixaban dosing and clinical characteristics in AF patients ...
JungMin Choi, So-Ryoung Lee, So-Ryoung Lee, Soonil Kwon, Hyo-Jeong Ahn, Kyung-Yeon Lee, Jong-Sung Park, Jong-Il Choi, Sung Ho Lee, Jung Ho Heo, Il-Young Oh, Young Keun On, Hee Tae Yu, Kwang-No Lee, Nam-Ho Kim, Hyung Wook Park, Hyung Wook Park, Ki Hong Lee, Ki Hong Lee, Seung Yong Shin, Seil Oh, Seil Oh, Gregory Y. H. Lip, Gregory Y. H. Lip, Gregory Y. H. Lip, Seongwook Han, Eue-Keun Choi, Eue-Keun Choi   +27 more
doaj   +1 more source

Apixaban versus warfarin in nephrotic syndrome: thromboembolic events, bleeding risk and changes in profibrotic and inflammatory cytokines

Український Журнал Нефрології та Діалізу
Nephrotic syndrome (NS) is associated with a high risk of thromboembolic complications and activation of inflammatory and profibrotic pathways. The optimal anticoagulation strategy in NS remains uncertain. Objective.
I. Mykhaloiko, R. Yatsyshyn
doaj   +1 more source